2026-06-01T18:25:43Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1144212025-03-18T14:13:17Zcom_20.500.14352_14col_20.500.14352_15

New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo Valhondo Falcón, Margarita Marco, Isabel Martín-Fontecha Corrales, María Del Mar Vázquez Villa, María Del Henar Ramos Atance, José Antonio Berkels, Reinhard Lauterbach, Thomas Benhamú Salama, Bellinda López Rodríguez, María Luz We report the synthesis of new compounds 4–35 based on two different openings (A and B) of the chromane ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand 3. The synthesized compounds were assessed for binding affinity, selectivity, and functional activity at the 5-HT1AR. Selected candidates resulting from B opening were also evaluated for their potential antinociceptive effect in vivo and pharmacokinetic properties in vitro. Analogue 19 [2-(4-{[2-(2-ethoxyphenoxy)ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione] has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 2.3 nM; EC50 = 19 nM). Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ∼ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM). Interestingly, 19 (3 mg/kg, ip, and 30 mg/kg, po) caused significant attenuation of formalin-induced behavior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was reversed by the selective 5-HT1AR antagonist WAY-100635. Thus, the new 5-HT1AR agonist identified in this work, 19, exhibits oral analgesic activity, and the results herein represent a step toward identifying new therapeutics for the control of pain. 2025-01-15T11:38:37Z 2025-01-15T11:38:37Z 2013-10-24 journal article Valhondo, M., Marco, I., Martín-Fontecha, M., Vázquez-Villa, H., Ramos, J. A., Berkels, R., Lauterbach, T., Benhamú, B., López-Rodríguez, M. L. New Serotonin 5-HT1A Receptor Agonists Endowed with Antinociceptive Activity in Vivo. J. Med. Chem. 2013, 56 (20), 7851-7861 0022-2623 10.1021/jm400766k https://hdl.handle.net/20.500.14352/114421 1520-4804 https://doi.org/10.1021/jm400766k https://pubs.acs.org/doi/10.1021/jm400766k eng info:eu-repo/grantAgreement/MICINN//SAF2010-22198-C02-01/ES/DESARROLLO DE COMPUESTOS PARA LA VALIDACION E IDENTIFICACION DE DIANAS TERAPEUTICAS MEDIANTE QUIMICA GENOMICA DIRECTA E INVERSA/ S2010/BMD2353 http://creativecommons.org/licenses/by-nc-nd/4.0/ restricted access Attribution-NonCommercial-NoDerivatives 4.0 International ACS Publications